Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06206564 · ClinicalTrials.gov registry record · Phase 2
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
A Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL, sponsored by Frantz Viral Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT06206564 is a Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL that is actively recruiting participants, run by Frantz Viral Therapeutics. The registered enrollment target is 48 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06206564, a Phase 2 study of Anal High-grade Squamous Intraepithelial Lesion and Anal HSIL, is actively recruiting participants, sponsored by Frantz Viral Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Artesunate ointment
Study Locations (2)
Illinois
- Anal Dysplasia Clinic MidWest - Chicago
New York
- Laser Surgery Care - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-01-12 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06206564
The ClinicalTrials.gov registry entry for NCT06206564 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Frantz Viral Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anal High-grade Squamous Intraepithelial Lesion appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06206564 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06206564 about?
NCT06206564 is a clinical study titled "Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants". This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
What is the current status of trial NCT06206564?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-01-12. Estimated completion is 2026-12-31.
What conditions does trial NCT06206564 study?
This clinical trial studies the following conditions: Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN.
What interventions are being tested in trial NCT06206564?
The interventions under investigation include: Placebo (DRUG), Artesunate ointment (DRUG).
Who is sponsoring clinical trial NCT06206564?
This trial is sponsored by Frantz Viral Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06206564 being conducted?
This trial has 2 study locations across Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal High-grade Squamous Intraepithelial Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.